On March 10, 2025, IceCure Medical Ltd. announced the publication of an independent study in the peer-reviewed journal Gland Surgery, titled 'Post-treatment patient satisfaction in early-stage breast cancer: Comparison of cryoablation versus breast conservation therapy using BREAST-Q.' The study, conducted at the Breast Center, Kameda Medical Center in Japan, found that breast cancer patients who underwent ProSense® cryoablation reported significantly higher satisfaction and quality of life compared to those who underwent standard of care surgery.
Dr. Kizuki Matsumoto, a co-author of the article, highlighted the clinical importance of assessing health-related quality of life (HRQOL) and noted the limited studies examining long-term satisfaction following cryoablation, particularly in Asian patients. The study's positive outcomes suggest that cryoablation will become more widespread in the future, especially as breast cancer increasingly becomes a chronic disease where survivor quality of life is a major focus.
IceCure's CEO, Eyal Shamir, expressed gratitude for the study, stating that the data clearly demonstrate superior quality of life and patient satisfaction with cryoablation over traditional surgery for early-stage breast cancer. These results are expected to support IceCure's distribution partner, Terumo Corporation, in its application for regulatory approval of ProSense® for breast cancer in Japan.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.